AptarGroup (ATR) investor relations material

Executive summary

• Achieved record quarterly sales of $1.03 billion, up 6% year-over-year, with all three segments—Pharma, Beauty, and Closures—delivering revenue growth and adjusted EPS of $1.42, led by strong Pharma consumer healthcare and injectables demand.

• Adjusted EPS declined 15% year-over-year, while reported EPS was $1.36; net income for Q2 was $88 million.

• Returned $212 million to shareholders year-to-date via dividends and share repurchases, including $81 million in Q2.

• Leadership transition announced: Gael Touya to become CEO on September 1, 2026.

Financial highlights

• Q2 2026 net sales: $1.03 billion (+6% YoY); core sales up 1%; six-month net sales: $2.01 billion (+8% YoY).

• Q2 adjusted EBITDA: $213 million (20.7% margin, down from 22.6%); Q2 net income: $88 million (8.6% margin).

• Q2 adjusted EPS: $1.42 (down from $1.68 prior year); six-month adjusted EPS: $2.61 (down 12%).

• Free cash flow for six months: $99.2 million.

Outlook and guidance

• Q3 2026 adjusted EPS guidance: $1.45–$1.53, assuming a 22.5%–24.5% effective tax rate and 1.14 EUR/USD exchange rate.

• Full-year 2026 capital expenditures projected at $260–$280 million; D&A expense $310–$320 million.

• Emergency medicine destocking headwinds in Pharma expected to ease by Q4.

• Management expects continued growth across all segments, led by Pharma injectables and consumer healthcare.